» Articles » PMID: 38002335

Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence

Overview
Journal Biomolecules
Publisher MDPI
Date 2023 Nov 25
PMID 38002335
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is a complex and multifaceted disease with a high global incidence and mortality rate. Although cancer therapy has evolved significantly over the years, numerous challenges persist on the path to effectively combating this multifaceted disease. Natural compounds derived from plants, fungi, or marine organisms have garnered considerable attention as potential therapeutic agents in the field of cancer research. Ellagic acid (EA), a natural polyphenolic compound found in various fruits and nuts, has emerged as a potential cancer prevention and treatment agent. This review summarizes the experimental evidence supporting the role of EA in targeting key hallmarks of cancer, including proliferation, angiogenesis, apoptosis evasion, immune evasion, inflammation, genomic instability, and more. We discuss the molecular mechanisms by which EA modulates signaling pathways and molecular targets involved in these cancer hallmarks, based on in vitro and in vivo studies. The multifaceted actions of EA make it a promising candidate for cancer prevention and therapy. Understanding its impact on cancer biology can pave the way for developing novel strategies to combat this complex disease.

Citing Articles

Phytochemical Insights and Therapeutic Potential of and .

Kozhantayeva A, Iskakova Z, Ibrayeva M, Sapiyeva A, Arkharbekova M, Tashenov Y Molecules. 2025; 30(5).

PMID: 40076409 PMC: 11901623. DOI: 10.3390/molecules30051186.


Unveiling the Cytotoxic and NO Inhibitory Potential of Heliotropium dolosum Extracts from Türkiye: A First Insight Into Its Phenolic Profile.

Ozay C Plant Foods Hum Nutr. 2025; 80(1):86.

PMID: 40048043 PMC: 11885333. DOI: 10.1007/s11130-025-01313-y.


Comprehensive pharmacokinetic profiling and molecular docking analysis of natural bioactive compounds targeting oncogenic biomarkers in breast cancer.

Othman B, Beigh S, Albanghali M, Sindi A, Shanawaz M, Ibahim M Sci Rep. 2025; 15(1):5426.

PMID: 39948091 PMC: 11825887. DOI: 10.1038/s41598-024-84401-4.


Molecular Docking Appraisal of Phytochemicals as Potential Inhibitors of PI3K/Akt Pathway for Breast Cancer Treatment.

Effiong M, Bella-Omunagbe M, Afolabi I, Chinedu S Bioinform Biol Insights. 2025; 19:11779322251316864.

PMID: 39906062 PMC: 11792010. DOI: 10.1177/11779322251316864.


Ellagic acid alleviates NLRP6/caspase-1/GSDMD-mediated inflammation and pyroptosis in rats post cerebral ischemia/reperfusion injury.

Ling Hu , Wei X, Shen G, Huang X Iran J Basic Med Sci. 2025; 28(1):105-112.

PMID: 39877634 PMC: 11771333. DOI: 10.22038/ijbms.2024.78864.17057.


References
1.
Cang S, Iragavarapu C, Savooji J, Song Y, Liu D . ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol. 2015; 8:129. PMC: 4654800. DOI: 10.1186/s13045-015-0224-3. View

2.
Liu H, Zeng Z, Wang S, Li T, Mastriani E, Li Q . Main components of pomegranate, ellagic acid and luteolin, inhibit metastasis of ovarian cancer by down-regulating MMP2 and MMP9. Cancer Biol Ther. 2017; 18(12):990-999. PMC: 5718784. DOI: 10.1080/15384047.2017.1394542. View

3.
Kim J, Choi Y, Kim H . Determining the effect of ellagic acid on the proliferation and migration of pancreatic cancer cell lines. Transl Cancer Res. 2022; 10(1):424-433. PMC: 8798349. DOI: 10.21037/tcr-20-2446. View

4.
Saretzki G . Role of Telomeres and Telomerase in Cancer and Aging. Int J Mol Sci. 2023; 24(12). PMC: 10298412. DOI: 10.3390/ijms24129932. View

5.
Price E, Kolkiewicz K, Patel R, Hashim S, Karaa E, Scheimberg I . Detection and reporting of RB1 promoter hypermethylation in diagnostic screening. Ophthalmic Genet. 2018; 39(4):526-531. DOI: 10.1080/13816810.2018.1479432. View